News Headlines

  1. Recipharm Announces All Its Facilities Are Ready For EU Serialisation

    Recipharm, the contract development and manufacturing organisation (CDMO), recently announced that all fifteen of its facilities outlined in its investment plan are now fully prepared for drug serialisation and have delivered serialised batches within Europe ahead of the February 9th deadline.

  2. Single-Use Technology For Biologics Manufacturing In St. Louis, Missouri

    Watch this video and learn about Thermo Fisher Scientific’s expansion of its biologics site in St. Louis, Missouri. The facility will be the single largest single-use technology CDMO in the United States.

  3. Thermo Fisher Continues To Expand Its Outsourcing Capacity To Meet The Continued Strong Demand For Commercialization Services

    In 2018, the Pharma Services biologics business within Thermo Fisher Scientific, supported the commercialization of two new therapeutics for its clients. The St. Louis, Missouri and the Groningen, Netherlands sites both completed FDA Pre-Approval Inspections (PAIs) and received Establishment Inspection Reports (EIRs) for the commercial manufacture of biologic therapies.

  4. Lonza And AllCells Join Forces For Global Commercialization Of Hematopoietic Primary Cells

    Lonza and AllCells have entered into a private label partnership for the manufacture and global commercialization of an extensive range of hematopoietic primary cells.

  5. Lonza Announces Succession Of CEO

    Lonza announced recently that Richard Ridinger, CEO, has decided to retire from the company after seven successful years. Going forward, he intends to build a portfolio of non-executive positions in various companies.

  6. Particle Sciences Partners With Encube Ethicals To Develop Novel Vaginal Rings

    Contract development and manufacturing organization (CDMO), Particle Sciences, a Lubrizol LifeSciences company, has announced its partnership with leading Indian contract manufacturing organization (CMO), Encube Ethicals.

  7. FDA Approves First Generic Advair Diskus

    The U.S. Food and Drug Administration today approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).

  8. BioDuro Partners With Advent International

    BioDuro, a leading global life sciences contract research and development organization, and Advent International, one of the largest and most experienced global private equity investors, recently announced a partnership to support BioDuro’s growth as a premier provider of integrated drug discovery, development and manufacturing services.

  9. Wasdell Group Granted HPRA Licence At New EU Headquarters

    The Wasdell Group (Wasdell), a leading outsourcing partner for companies in the pharmaceutical and clinical trials industries, has been granted its Health Products Regulatory Authority (HPRA) licence for its new EU headquarters in Dundalk, Ireland.

  10. Lonza To Commence Commercial Supply Of Portola’s Second-Generation Andexxa

    Following the recent U.S Food and Drug Administration (FDA) approval of the Prior Approval Supplement (PAS) for second-generation Andexxa, Portola Pharmaceuticals, Inc. and Lonza announce the start of commercial supply of the recombinant coagulation factor from Lonza’s Porriño (ES) facility.